FOXM1 has also been shown to promote taxane resistance in breast cancer [216,264,265], gastric cancer [266,267,268], hepatocellular carcinoma [269], prostate cancer [270], and nasopharyngeal carcinoma [271]. Here, FOXM1 is linked to gastric cancer.